SCHEMBL5890384

SCHEMBL5890384

Clc1cccc(-c2nn3c(Cl)cc(Cl)cc3c2-c2ccnc(NC3CCCC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.48
EIF2AK2 P19525 1/20 0.47
MAPK10 P53779 3/20 0.43
MAPK1 P28482 4/20 0.43
MAPK8 P45983 3/20 0.42
MAPK9 P45984 3/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
IKBKB O14920 2/20 0.41
CDK4 P11802 3/20 0.41
CCNA2 P20248 3/20 0.41
CDK2 P24941 3/20 0.41
MAPK3 P27361 3/20 0.41
GSK3B P49841 1/20 0.40
DGAT1 O75907 1/20 0.40
PLK1 P53350 1/20 0.40
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5890757 0.92 ADORA1 (0.48) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL6106438 0.89 ADORA1 (0.48) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL5875556 0.88 EIF2AK2 (0.46) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL5455917 0.88 ADORA1 (0.48) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL6106109 0.88 ADORA1 (0.48) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL6106728 0.88 ADORA1 (0.48) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL5456176 0.87 ADORA1 (0.47) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL5890649 0.87 CSNK1D (0.51) EIF2AK2MAPK10MAPK1MAPK8MAPK9
SCHEMBL5447692 0.85 EIF2AK2 (0.47) ADORA1EIF2AK2MAPK10MAPK1MAPK8
SCHEMBL6108047 0.85 CDK4 (0.47) ADORA1EIF2AK2MAPK10MAPK1MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 US claimed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP claimed
US-20040142941-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2004-07-22 US claimed
US-7030134-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-04-18 US disclosed
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 US disclosed
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds GUDMUNDSSON KRISTJAN (US) 2005-09-01 US disclosed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP disclosed
US-20040142941-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142941-A1 Therapeutic compounds PCSK9, ABCB1, ABCB11 ADORA1 277/4885EIF2AK2 3551/4885MAPK10 2318/4885
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds DPYD, TYMP, P2RY4 ADORA1 522/4885EIF2AK2 1588/4885MAPK10 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.